Since it FDA approval in 2004, docetaxel (a taxane based chemotherapy) has been the standard first-line chemotherapy for men with metastatic prostate cancer (mCRPC). Other than the trial of Provenge all the successful phase III trials conducted in mCRPC focused on men experiencing cancer progression after first-line docetaxel chemotherapy. The implication is that improving the [...]
Approximately one third of all men diagnosed and treated for prostate cancer will experience a recurrence of their prostate cancer! This is a shocking number, but it is a true number. It does not matter what the treatment a man has, the statistic holds up across all treatments. The first sign of a problem, a [...]
Start A Cure Research Project of the Day A Simple and Novel Approach to Enhance the Efficacy of Intermittent Androgen Deprivation Therapy for Prostate Cancer Patients There comes a time when most of us will go on to Androgen Deprivation Therapy (ADT). Depending upon your philosophy, your doctors philosophy and your numbers (Gleason grade and [...]
Xgeva is a monoclonal antibody that inactivates RANKL, a protein that enhances osteoclast activity and survival. By inhibiting RANKL, Xgeva prevents skeletal-related events in men with bone metastasis from prostate cancer. Under no circumstances should a man who also has multiple myeloma use Xgeva. There have been studies that compared Xgeva to zolendronic acid (Zometa). [...]
I have often discussed the importance of the Prostate Cancer Research Program (PCRP), which is a part of the Department of Defense (DOD) Medical Research Program. The program is geared to delivering funding for prostate cancer research that is translational, or will be quickly interpreted in the clinic. Like all other government funding it very [...]
Sequencing of the various new advanced prostate cancer treatments remains a hot topic in our community. What treatment should come first and will the combination of various treatments be even more effective? These types of questions are constantly buzzing around us and they will continue to as long as we develop new treatments. The only [...]
Some good news for men who are living in Japan and dealing with advanced prostate cancer. It was announced that Astellas and Medivation have submitted an application for marketing approval of Enzalutamide (Xtandi) in Japan. Their application is based on results obtained from the global Phase 3 trial (the AFFIRM trial)* and a Phase 1-2 [...]
The following is a post from Chuck Maack on the Advanced Prostate Cancer Internet support group: “It came to mind wondering how many patients and/or their caregivers prescribed Zytiga/abiraterone acetate have ever taken the important time to read all the details regarding the effects that may be experienced by patients and whether or not they [...]
The news is in, and it is bad. It is as bad as many of us feared. The National Institute of Health (NIH) has announced that their across-the-board budget sequester cuts are going to equal 1.71 billion dollars. The NIH is responsible for the majority of cancer research performed in the United States. For the [...]
I want to share that I am hopeful that we have made progress with Bayer Healthcare and the issues I have written about surrounding the newly approved treatment for men with castrate resistant prostate cancer, Xofigo. I have shared that they failed to support the early access trials because of what they claimed were supply [...]
